(Alliance News) - IQ-AI Ltd on Thursday said subsidiary Imaging Biometrics LLC has signed an agreement to distribute AI Metrics LLC's LSN image analysis product.
LSN is a platform designed by AI Metrics as a virtual liver biopsy, evaluating liver surface nodularity to assess chronic liver disease.
Currently, clinicians assess patient liver condition via surgical biopsy, which is prone to sampling error, pain, bleeding, and other complications, IQ-AI explained.
"The ability to non-invasively and accurately assess chronic liver disease is exciting for clinicians and will ultimately benefit patients," said Michael Schmainda, director of Imaging Biometrics.
IQ-AI shares were trading 1.5% lower in London on Thursday at 4.73 pence each.
By Evelina Grecenko; evelinagrecenko@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
Iq-ai Ltd (IQAI)